News Article | May 17, 2017
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced that data from a broad range of company-sponsored and investigator-initiated studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the American Society of Clinical Oncology Annual Meeting between June 2-6 in Chicago, Ill. “We are part of an extremely exciting time in cancer research, where accelerating deep insights into the biology of disease and tumor microenvironment are leading to approaches that have the potential to make a major impact on patients’ lives,” said Michael Pehl, President, Hematology and Oncology for Celgene. “The studies being shared at ASCO this year reinforce our commitment to developing and delivering innovative treatment options to patients with cancer around the world.” In multiple myeloma, abstracts will continue to support the role of Celgene’s IMiD® therapies as the foundation of multiple myeloma research, including in the maintenance setting. Additionally, data will be presented from the study evaluating the investigational R2 regimen (REVLIMID® (lenalidomide) and rituximab combination), in previously-treated follicular lymphoma. Updated data from two studies in the ABOUND program evaluating ABRAXANE® (nab-paclitaxel) in non-small cell lung cancer will also be presented. Finally, results from multiple studies highlighting key Celgene research collaborations of investigational compounds will be presented, including updated data from a phase I dose escalation and expansion study of IDHIFA® (enasidenib) in patients with mutant-IDH2 relapsed/refractory acute myeloid leukemia, updated data from the first clinical study of anti-BCMA CAR-T therapy bb2121 in multiple myeloma, and results from a study of CAR-T therapy JCAR017 in previously-treated aggressive b-cell non-Hodgkin’s lymphoma. Abstract #8000; Oral; Sunday, June 4, 9:45 a.m., E354b, Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase Ib study (Jakubowiak) Abstract #8001; Oral; Sunday, June 4, 9:57 a.m., E354b, Lenalidomide, adriamycin and dexamethasone versus bortezomib, lenalidomide and dexamethasone prior to scheduled stem cell transplant in newly diagnosed multiple myeloma (Knop) Abstract #8002; Oral; Sunday, June 4, 10:09 a.m., E354b, An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma (Laubach) Abstract #8009; Poster Discussion; Monday, June 5, 3:00 p.m., E354b, Lenalidomide induction and maintenance therapy for myeloma: Results of the Myeloma XI Study (Jackson) Abstract #8023; Poster; Monday, June 5, 8:00 a.m., Hall A, Impact of t(11;14) on outcomes in African American (AA) and non-AA (NAA) patients (Pts) with newly diagnosed multiple myeloma (NDMM): Connect® MM Registry (Gasparetto) Abstract #8007; Oral; Sunday, June 4, 11:57 a.m., E354b, A phase Ib study of isatuximab in combination with pomalidomide (Pom) and dexamethasone (Dex) in relapsed/refractory multiple myeloma (RRMM) (Mikhael) Abstract #8008; Oral; Sunday, June 4, 12:09 p.m., E354b, Phase I/II dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (Ben-Pom-d) in patients with relapsed/refractory multiple myeloma (Sivaraj) Abstract #8015; Poster Discussion; Monday, June 5, 3:00 p.m., E354b, Pembrolizumab (Pembro) plus lenalidomide (Len) and low-dose dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Efficacy and biomarker analyses (Ocio) Abstract #8027; Poster; Monday, June 5, 8:00 a.m., Hall A, Phase II study of pomalidomide (POM) + low-dose dexamethasone (LoDEX) following second-line lenalidomide (LEN)-based treatment (Tx) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): An updated analysis of efficacy and safety (Siegel) Abstract #8037; Poster; Monday, June 5, 8:00 a.m., Hall A, CALGB/ECOG 100104 (Alliance) study: Lenalidomide (LEN) vs placebo (PBO) maintenance (Maint) after stem cell transplant (SCT) for patients (Pts) with multiple myeloma: Overall survival (OS) and progression-free survival (PFS) adjusted for treatment (Tx) crossover (XO) (McCarthy) Abstract #8040; Poster; Monday, June 5, 8:00 a.m., Hall A, Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect® MM Registry (Jagannath) Abstract #7004; Oral; Tuesday, June 6, 10:57 a.m., E450ab, Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study (Stein) Abstract #7015; Poster Discussion; Monday, June 5, 11:30 a.m., E354b, Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) (Fathi) Abstract #7022; Poster; Monday, June 5, 8:00 a.m., Hall A, Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia (AML) enrolled in the CONNECT® MDS/AML Disease Registry (Pollyea) Abstract #7502; Oral; Saturday, June 3, 3:24 p.m., S100bc, Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL) (Andorsky) Abstract #7503; Oral; Saturday, June 3, 4:00 p.m., S100bc, A genetic risk-stratified, phase II study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Final results of Cancer and Leukemia Group B (CALGB) 10404 (Ruppert) Abstract #7513; Poster Discussion; Monday, June 5, 1:15 p.m., E354b, CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001) (Abramson) Abstract #9058; Poster; Saturday, June 3, 8:00 a.m., Hall A, Safety and efficacy of nab-paclitaxel (nab-P)–based therapy in patients (pts) with non-small cell lung cancer (NSCLC) and performance status (PS) 2: Results from ABOUND.PS2 (Gajra) Abstract #9059; Poster; Saturday, June 3, 8:00 a.m., Hall A, ABOUND.70+: Safety and efficacy of nab-paclitaxel/carboplatin (nab-P/C) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) (Langer) Abstract #9092; Poster; Saturday, June 3, 8:00 a.m., Hall A, Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study (Liu) Abstract #9095; Poster; Saturday, June 3, 8:00 a.m., Hall A, Nivolumab (nivo) + nab-paclitaxel (nab-P) + carboplatin (C) in patients (pts) with non-small cell lung cancer (NSCLC): Interim results from a multicenter phase I study (Waterhouse) Abstract #9095; Poster; Saturday, June 3, 8:00 a.m., Hall A, A phase II trial of gemcitabine (G), cisplatin (C), and nab-paclitaxel (N) in advanced biliary tract cancers (aBTCs) (Shroff) The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. A complete listing of abstracts can be found on the ASCO website at http://am.asco.org/program ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine. Postmarketing Experience With ABRAXANE and Other Paclitaxel Formulations REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of patients with multiple myeloma (MM) REVLIMID is indicated as maintenance therapy in patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT) REVLIMID® is indicated for the treatment of patients with transfusion-dependent anemia due to low-or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities REVLIMID® is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials Do not use REVLIMID during pregnancy. Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If lenalidomide is used during pregnancy, it may cause birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy tests before starting REVLIMID treatment. Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after REVLIMID treatment. To avoid embryo-fetal exposure to lenalidomide, REVLIMID is only available through a restricted distribution program, the REVLIMID REMS® program). Information about the REVLIMID REMS® program is available at www.celgeneriskmanagement.com or by calling the manufacturer’s toll-free number 1-888-423-5436. REVLIMID can cause significant neutropenia and thrombocytopenia. Eighty percent of patients with del 5q MDS had to have a dose delay/reduction during the major study. Thirty-four percent of patients had to have a second dose delay/reduction. Grade 3 or 4 hematologic toxicity was seen in 80% of patients enrolled in the study. Patients on therapy for del 5q MDS should have their complete blood counts monitored weekly for the first 8 weeks of therapy and at least monthly thereafter. Patients may require dose interruption and/or reduction. Patients may require use of blood product support and/or growth factors. REVLIMID has demonstrated a significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as risk of myocardial infarction and stroke in patients with MM who were treated with REVLIMID and dexamethasone therapy. Monitor for and advise patients about signs and symptoms of thromboembolism. Advise patients to seek immediate medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. Thromboprophylaxis is recommended and the choice of regimen should be based on an assessment of the patient’s underlying risks. Pregnancy: REVLIMID can cause fetal harm when administered to a pregnant female and is contraindicated in females who are pregnant. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to the fetus Allergic Reactions: REVLIMID is contraindicated in patients who have demonstrated hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide REVLIMID REMS® Program: See Boxed WARNINGS: Prescribers and pharmacies must be certified with the REVLIMID REMS program by enrolling and complying with the REMS requirements; pharmacies must only dispense to patients who are authorized to receive REVLIMID. Patients must sign a Patient-Physician Agreement Form and comply with REMS requirements; female patients of reproductive potential who are not pregnant must comply with the pregnancy testing and contraception requirements and males must comply with contraception requirements Hematologic Toxicity: REVLIMID can cause significant neutropenia and thrombocytopenia. Monitor patients with neutropenia for signs of infection. Advise patients to observe for bleeding or bruising, especially with use of concomitant medications that may increase risk of bleeding. MM: Patients taking REVLIMID/dex or REVLIMID maintenance therapy should have their complete blood counts (CBC) assessed every 7 days for the first 2 cycles, on days 1 and 15 of cycle 3, and every 28 days thereafter. MDS: Patients on therapy for del 5q MDS should have their complete blood counts monitored weekly for the first 8 weeks of therapy and at least monthly thereafter. Patients may require dose interruption and/or dose reduction. Please see the Black Box WARNINGS for further information. MCL: Patients taking REVLIMID for MCL should have their CBCs monitored weekly for the first cycle (28 days), every 2 weeks during cycles 2-4, and then monthly thereafter. Patients may require dose interruption and/or dose reduction Venous and Arterial Thromboembolism: See Boxed WARNINGS: Venous thromboembolic events (DVT and PE) and arterial thromboses (MI and CVA) are increased in patients treated with REVLIMID. Patients with known risk factors, including prior thrombosis, may be at greater risk and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). Thromboprophylaxis is recommended and the regimen should be based on patient’s underlying risks. ESAs and estrogens may further increase the risk of thrombosis and their use should be based on a benefit-risk decision Increased Mortality in Patients with CLL: In a clinical trial in the first-line treatment of patients with CLL, single agent REVLIMID therapy increased the risk of death as compared to single agent chlorambucil. Serious adverse cardiovascular reactions, including atrial fibrillation, myocardial infarction, and cardiac failure, occurred more frequently in the REVLIMID arm. REVLIMID is not indicated and not recommended for use in CLL outside of controlled clinical trials Second Primary Malignancies (SPM): In clinical trials in patients with MM receiving REVLIMID, an increase of hematologic plus solid tumor SPM, notably AML and MDS, have been observed. Monitor patients for the development of SPM. Take into account both the potential benefit of REVLIMID and risk of SPM when considering treatment Hepatotoxicity: Hepatic failure, including fatal cases, has occurred in patients treated with REVLIMID/dex. Pre-existing viral liver disease, elevated baseline liver enzymes, and concomitant medications may be risk factors. Monitor liver enzymes periodically. Stop REVLIMID upon elevation of liver enzymes. After return to baseline values, treatment at a lower dose may be considered Allergic Reactions: Angioedema and serious dermatologic reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported. These events can be fatal. Patients with a prior history of Grade 4 rash associated with thalidomide treatment should not receive REVLIMID. REVLIMID interruption or discontinuation should be considered for Grade 2-3 skin rash. REVLIMID must be discontinued for angioedema, Grade 4 rash, exfoliative or bullous rash, or if SJS or TEN is suspected and should not be resumed following discontinuation for these reactions. REVLIMID capsules contain lactose; risk-benefit of treatment should be evaluated in patients with lactose intolerance Tumor Lysis Syndrome (TLS): Fatal instances of TLS have been reported during treatment with lenalidomide. The patients at risk of TLS are those with high tumor burden prior to treatment. These patients should be monitored closely and appropriate precautions taken Tumor Flare Reaction (TFR): TFR has occurred during investigational use of lenalidomide for CLL and lymphoma. Monitoring and evaluation for TFR is recommended in patients with MCL. Tumor flare may mimic the progression of disease (PD). In patients with Grade 3 or 4 TFR, it is recommended to withhold treatment with REVLIMID until TFR resolves to ≤ Grade 1. REVLIMID may be continued in patients with Grade 1 and 2 TFR without interruption or modification, at the physician’s discretion Impaired Stem Cell Mobilization: A decrease in the number of CD34+ cells collected after treatment (>4 cycles) with REVLIMID has been reported. Consider early referral to transplant center to optimize timing of the stem cell collection Thyroid Disorders: Both hypothyroidism and hyperthyroidism have been reported. Measure thyroid function before start of REVLIMID treatment and during therapy Periodic monitoring of digoxin plasma levels is recommended due to increased C and AUC with concomitant REVLIMID therapy. Patients taking concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thrombosis. It is not known whether there is an interaction between dex and warfarin. Close monitoring of PT and INR is recommended in patients with MM taking concomitant warfarin POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. POMALYST is only available through a restricted distribution program called POMALYST REMS®. Nearly all patients treated with POMALYST + low-dose dex experienced at least one adverse reaction (99%). The most common adverse reactions included neutropenia (51.3%), fatigue and asthenia (46.7%), upper respiratory tract infection (31%), thrombocytopenia (29.7%), pyrexia (26.7%), dyspnea (25.3%), diarrhea (22%), constipation (21.7%), back pain (19.7%), cough (20%), pneumonia (19.3%), bone pain (18%), edema peripheral (17.3%), peripheral neuropathy (17.3%), muscle spasms (15.3%), and nausea (15%). Grade 3 or 4 adverse reactions included neutropenia (48.3%), thrombocytopenia (22%), and pneumonia (15.7%). Avoid concomitant use of POMALYST with strong inhibitors of CYP1A2. Consider alternative treatments. If a strong CYP1A2 inhibitor must be used, reduce POMALYST dose by 50%. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube. This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. Celgene undertakes no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in Celgene’s Annual Report on Form 10-K and other reports filed with the Securities and Exchange Commission.
News Article | May 19, 2017
Contemporary Information Corporation™ (CIC™), the nation’s leading provider of resident and employment screening since 1986, is proud to announce that they will be exhibiting at National Apartment Association’s (NAA) 2017 Education and Conference and Exposition in Atlanta, Georgia. Joining nearly 10,000 apartment housing professionals for the 10th consecutive year, CIC™ is excited to showcase their new property management software, CICTotal Manager™ at the Georgia World Congress Center from June 21-24th. The tenant screening company invites multifamily executives and property managers to connect with their team at Booth #2901 to learn how they can protect their rental communities with nationwide resident screening, employment screening, and other property tools. CIC™ also welcomes attendees to add them to their myNAA planner as they will be raffling away three Kate Spade handbags and handing out free items throughout the conference. Alongside the company’s comprehensive credit and background reports, CIC™ is proud to showcase their all-inclusive property management software, CICTotal Manager™, to National Apartment Association members and guests! This intuitive software empowers property management companies with features like real-time marketing analytics, accounting, in-software resident messaging, automatic rent collections, online leasing, and more, all for an affordable subscription fee of just $1 per unit, per month (with a $200 minimum). No hidden fees, no software to purchase. Booth #2901 will also feature a demo of the new software and a free 30-day trial with CICTotal Manager™ will be available to attendees who stop by. CIC™ is eager to share their passion for best-in-class resident and employment screening and property management solutions. To schedule a meeting before the conference, simply fill out the contact form at http://www.cicreports.com or call Dan Firestone at 888-232-3822.
News Article | May 22, 2017
Lori Lemons-Campbell is Co-Owner and General Manager in the daily operations of Lemons Auctioneers & Online Pros The Texas Auctioneers Association held their 60th Anniversary Annual Convention and Championship Contest May 7-9 in Frisco, Texas. During this convention, the Texas Auctioneers Hall of Fame inductee is announced and is not known to anyone except the awards committee. The 2017 Hall of Fame inductee was Lori Lemons-Campbell of Tomball, Texas. She is the first woman to be inducted into the Texas Auctioneers Hall of Fame and is a 2nd generation auctioneer. She began in the auction industry as a child helping her father, Del Lemons, and mother, Patti Franklin of Groesbeck, TX. Her father was also awarded into the Hall of Fame in 2009. Lori, her sister Jackie Lemons-Shillingburg and family continue to run their auction business in addition to expanding it to include online auctions and real estate. Lori is Co-Owner and General Manager in the daily operations of Lemons Auctioneers & Online Pros. She also serves as Co-Owner and President of My Real Estate Expert, LLC., a growing real estate company and an affiliate of Lemons Auctioneers, LLP. Lori’s experience includes the liquidation of assets for major oil companies, exploration companies, business liquidations, banking and lending institutions, small business administration, geophysical companies, cities, counties, learning institutions, real estate and many specialized industries. She is an NAA graduate of the Certified Auctioneers Institute (CAI) of 2010 and a Past President of the Texas Auctioneers Association (2014-2015). Lori is passionate about working hard to achieve continued growth and success in the Auction Industry. She resides in the Tomball/Magnolia area with her husband, Jeff, of 28 years and enjoys swimming, running, fishing, hunting, and spending time with her family and grandchildren.
News Article | May 16, 2017
National Aviation Academy (NAA) and Delta TechOps today announce a partnership to assist in meeting the critical demand for qualified aviation maintenance technicians within the aviation industry. Aviation Maintenance Technicians (AMTs) keep aircraft in safe flying condition by servicing, repairing and overhauling aircraft and aircraft components while following detailed manufacturer specifications and federal regulations set by the Federal Aviation Administration (FAA). AMTs are in high demand as the industry expands and technicians age out of the aviation workforce. 38 AMT schools were selected to work with Delta to prepare for the hiring need, which is projected to exceed 679,000 technicians by 2035, according to Boeing’s 2016 Pilot and Technician Outlook. NAA was subject to a strict evaluation process and was found to meet FAA standards as well as Delta’s high principles that exceed industry standards. Educational programming at NAA will benefit from Delta as a resource for continuous improvement. Additionally, partnering with Delta will broaden student access to AMT careers available within the global aviation industry. “Delta consistently delivers innovation, leadership and teamwork at the highest level. Students will benefit immeasurably from this partnership as we work together to produce quality aviation maintenance professionals,” said David Mead, Senior Executive Vice President for NAA. NAA incorporates the latest technology and industry resources to deliver high quality aviation maintenance training. Partnering with Delta TechOps will strengthen NAA’s ability to achieve its mission of preparing students for employment in the aviation industry.
News Article | April 21, 2017
Receive press releases from All 4 One Tutoring: By Email All 4 One Tutoring Celebrates the Heart of Afterschool Programs During Afterschool Professionals Appreciation Week April 24-28, 2017 Baltimore, MD, April 21, 2017 --( “We believe Afterschool professionals make a difference in the life of a child,” said Dr. Charice Hayes, owner of All 4 One Tutoring. “We encourage everyone to join us this week in thanking the afterschool professionals in their lives.” Why is it important to recognize Afterschool Professionals? An estimated 10.2 million children participate in afterschool programs each year. Today, afterschool programs are viewed as much more than just childcare. They are widely credited as the way to enhance education in STEM, literacy, the arts, social and emotional learning, health and wellness, and more. With that demand comes increased responsibility on the estimated 850,000 of professionals who are making a difference in the lives of our children. What is Afterschool Professionals Appreciation Week? Afterschool Professionals Appreciation Week is a joint effort of community partners, afterschool programs, youth and child care workers, and individuals who have committed to dedicating time to recognize and appreciate those who work with youth during out-of-school hours. The week is marked by celebrations and public relations efforts to encourage people to thank afterschool professionals serving children in programs and organizations across the nation. Who is an Afterschool Professional? An Afterschool Professional is someone who works with children and youth in diverse school and community-based settings to provide a wide variety of extended learning opportunities and care during out-of-school hours. Currently, there is an estimated 850,000 afterschool professionals in the US. How can I thank an Afterschool Professional? · Declare on social media: I appreciate the Afterschool Professionals who make a difference in the life of a child. #heartofafterschool · Give a hand-written card from you and/or your child to the afterschool professional in your life. · Send an email to an afterschool professional’s supervisor describing why that person is appreciated. · Make treats for the staff at your afterschool program. · Join the movement by donating your social media influence at http://bit.ly/heartofafterschool17 For more information about Afterschool Professionals Appreciation Week visit: http://www.heartofafterschool.com Baltimore, MD, April 21, 2017 --( PR.com )-- All 4 One Tutoring is joining with the National AfterSchool Association (NAA) to celebrate the professionals that are at the heart of afterschool programs during “Afterschool Professionals Appreciation Week” April 24-28, 2017.“We believe Afterschool professionals make a difference in the life of a child,” said Dr. Charice Hayes, owner of All 4 One Tutoring. “We encourage everyone to join us this week in thanking the afterschool professionals in their lives.”Why is it important to recognize Afterschool Professionals?An estimated 10.2 million children participate in afterschool programs each year. Today, afterschool programs are viewed as much more than just childcare. They are widely credited as the way to enhance education in STEM, literacy, the arts, social and emotional learning, health and wellness, and more. With that demand comes increased responsibility on the estimated 850,000 of professionals who are making a difference in the lives of our children.What is Afterschool Professionals Appreciation Week?Afterschool Professionals Appreciation Week is a joint effort of community partners, afterschool programs, youth and child care workers, and individuals who have committed to dedicating time to recognize and appreciate those who work with youth during out-of-school hours. The week is marked by celebrations and public relations efforts to encourage people to thank afterschool professionals serving children in programs and organizations across the nation.Who is an Afterschool Professional?An Afterschool Professional is someone who works with children and youth in diverse school and community-based settings to provide a wide variety of extended learning opportunities and care during out-of-school hours. Currently, there is an estimated 850,000 afterschool professionals in the US.How can I thank an Afterschool Professional?· Declare on social media: I appreciate the Afterschool Professionals who make a difference in the life of a child. #heartofafterschool· Give a hand-written card from you and/or your child to the afterschool professional in your life.· Send an email to an afterschool professional’s supervisor describing why that person is appreciated.· Make treats for the staff at your afterschool program.· Join the movement by donating your social media influence at http://bit.ly/heartofafterschool17For more information about Afterschool Professionals Appreciation Week visit: http://www.heartofafterschool.com Click here to view the list of recent Press Releases from All 4 One Tutoring
News Article | June 19, 2017
SANTA BARBARA, Calif.--(BUSINESS WIRE)--The annual NAA Education Conference & Exposition is one of the apartment industry’s premier events, and each year Yardi experts and clients are enthusiastic contributors. This year the “Apartmentalize” themed conference is taking place June 21-24 at the Georgia World Congress Center in Atlanta, Georgia. Yardi is an Alliance Partner and Education Conference & Expo Partner. Yardi clients will discuss their experiences and provide valuable insight into industry trends on Wednesday, June 21 in the “Living Room Learning” sessions “Achieving Big Results with Tiny Apartment Homes” and “The Truth about eLearning: Five Myths Debunked.” On Thursday, June 22, Yardi experts and clients will participate on panels to share invaluable knowledge about revenue management, business intelligence, marketing and energy. For more details on these sessions and panels, visit Yardi at NAA 2017. And to keep attendees invigorated during the event, the Yardi Energy Bar at Booth #2821 will offer device charging stations, coffee, energy drinks and snacks. To view a complete list of NAA sessions and activities, view the NAA conference schedule. The National Apartment Association (NAA) is the leading voice for the apartment housing industry. As a trusted partner, a valued connector and a powerful advocate, NAA is committed to serving 170 affiliates, over 72,000 members and the 8.8 million apartment units they operate globally. For more information, visit naahq.org. Yardi® develops and supports industry-leading investment and property management software for all types and sizes of real estate companies. Established in 1984, Yardi is based in Santa Barbara, Calif., and serves clients worldwide. For more information on how Yardi is Energized for Tomorrow, visit yardi.com.
News Article | February 15, 2017
PRG Real Estate, a leading multifamily real estate investment and management firm, announced today the acquisition of The Resort at Lake Crossing Apartments, located in Lexington, KY. The Resort at Lake Crossing is a 208-unit garden-style apartment community located along the major thoroughfare of Richmond Road. The community’s location provides proximity to major employers such as IBM, Lexmark, and Trane along with regional attractions such as The University of Kentucky, Jacobson Park, and the Keeneland Horse Racing Track. Built in 1999, The Resort at Lake Crossing provides a favorable mix of 1, 2 and 3 bedroom units with spacious floorplans averaging over 1,000 square feet. Unit interiors are well-appointed with oversized bathtubs, wood burning fireplaces, vaulted ceilings and large patios or balconies. The property also has a wide variety of unique amenities to offer residents such as a saltwater pool and sundeck, 24-hour health and fitness center and a full-service coffee bar and picnic area. PRG plans to further enhance the community by redecorating the clubhouse and upgrading the apartment homes with new appliances, flooring and fixtures. “PRG is excited to assume ownership and management of Resort At Lake Crossing which will be our 4th acquisition in the Lexington market,” states CEO Sam Foster. “We have found that hands on management and focused customer service is the key to success. Our planned capital improvements will enhance both the apartment interiors as well as common area amenity space, improving the resident living experience and increasing the value of the property.” Founded in 1985 by Steven Berger and Jon Goodman, PRG Real Estate is a Philadelphia based real estate firm that acquires and manages quality apartment communities throughout the eastern half of the United States. Since its founding, PRG has acquired well over 50 communities and 13,000 apartment units. PRG also has been designated as an Accredited Management Organization by the Institute of Real Estate Management (IREM) and holds membership in the National Apartment Association (NAA) as well as the National Multifamily Housing Council (NMHC). For more information please visit http://www.prgrealestate.com
News Article | March 2, 2017
WASHINGTON--(BUSINESS WIRE)--Statement from the National Multifamily Housing Council (NMHC) and National Apartment Association (NAA) following Dr. Ben Carson’s confirmation as the Secretary of the Department of Housing and Urban Development (HUD): “NMHC and NAA congratulate Secretary Carson on his confirmation and as an industry, we look forward to working with him and his team to develop a balanced housing policy that recognizes the importance of a strong housing market for both rental and home ownership. “President Trump’s recent comments before Congress and Secretary Carson’s confirmation are encouraging signs that the new administration is committed to working with the apartment industry to reduce burdensome regulations that create compliance uncertainty and result in costly mandates that divert resources from the production and operation of multifamily housing. “With the number of households renting apartments standing at an all-time high of almost 19 million, it has never been more important that private industry and lawmakers come together in support of pro-growth policies that make it easier for American residents and families to find housing that fits their unique needs and circumstances and that helps them contribute to their communities. A modern, comprehensive housing policy will create millions of jobs and align housing supply with demand.” More information about apartments is available at www.weareapartments.org. For more than 20 years, the National Apartment Association (NAA) and the National Multifamily Housing Council (NMHC) have partnered on behalf of America’s apartment industry. Drawing on the knowledge and policy expertise of staff in Washington, D.C., as well as the advocacy power of 170 NAA state and local affiliated associations, NAA and NMHC provide a single voice for developers, owners and operators of multifamily rental housing. Apartments and their 39 million residents support more than 12 million jobs and contribute $1.3 trillion to the economy.
News Article | March 1, 2017
WASHINGTON--(BUSINESS WIRE)--Statement from the National Multifamily Housing Council (NMHC) and National Apartment Association (NAA) following President Trump’s Address to a Joint Session of Congress: “We support President Trump’s efforts to strengthen economic growth and expand job creation. As the industry that houses 39 million residents, supports over 12 million jobs and contributes $1.3 trillion to the economy, the President’s direct focus on issues of critical importance to the apartment industry such as tax reform, infrastructure investment and rolling back burdensome regulations is commendable. “Today, there are over 43 million renter households and Harvard’s Joint Center for Housing Studies believes that demand for renter households could increase by as much as 4.4 million by 2025. The multifamily sector is under increasing pressure to meet that booming demand across the country, yet, excessive regulation and compliance uncertainty results in costly mandates that make it impossible to develop and operate multifamily housing. “NMHC/NAA applaud the Administration’s efforts to overhaul the federal regulatory landscape. To that end, we look forward to working with the Trump Administration and leaders in Congress to develop policies that drive investment, spark development and remove barriers and remove burdens on current operators, supporting the future growth of the apartment industry.” More information about apartments is available at www.weareapartments.org. For more than 20 years, the National Apartment Association (NAA) and the National Multifamily Housing Council (NMHC) have partnered on behalf of America’s apartment industry. Drawing on the knowledge and policy expertise of staff in Washington, D.C., as well as the advocacy power of 170 NAA state and local affiliated associations, NAA and NMHC provide a single voice for developers, owners and operators of multifamily rental housing. Apartments and their 39 million residents support more than 12 million jobs and contribute $1.3 trillion to the economy.
News Article | February 15, 2017
ManagInc is pleased to announce that Jen Piccotti is joining the company. Jen will serve as Chief Operating Officer and partner at the multifamily industry’s first Corporate Social Responsibility (CSR) planning platform and consulting service. Jen rejoins her former SatisFacts partners Doug Miller (ManagInc founder and CEO) and Joe Summers (Chief Revenue Officer, partner). In her new role, Jen will oversee the company’s Everyone Can Win® CSR planning platform, as well as client training, support programs, and industry education. She will work closely with Joanna Naszlin, ManagInc’s Director of Marketing. Prior to joining ManagInc, Jen was SatisFacts’ SVP of Education and Marketing for nearly a decade. In that role, Jen led client support and brand management for SatisFacts and ApartmentRatings.com, and provided client resources through resident retention programs, customer service education, action planning, reputation management coaching, and content development. Jen has established herself as a multifamily industry authority on resident and employee engagement and retention. A noted author and highly followed blogger, she has spoken at such industry events as NAA, AIM, Multifamily Social Media Summit and Canada's Landlord WebCon. “I’m so excited to be working with Jen again after nearly a decade together at SatisFacts,” stated Doug Miller, founder and CEO of ManagInc. Continuing, Miller shared, “Jen’s DNA and expertise are a perfect fit with ManagInc’s mission of helping companies become more socially conscious and responsible – empowering clients to increase their focus on those who make their success possible. That includes improving the satisfaction, engagement and retention of their employees and residents, creating even more loyal service providers, as well as giving back to society in a meaningful way.” “This is such an incredible opportunity to join Doug and Joe in being champions of change in our industry. Doug has always preached the power of putting people first, and I’ve seen his philosophy work first hand. I’m looking forward to working with our clients to educate and empower their employees, customers and vendors to set each other and their communities up for success.” About ManagInc Baltimore-based ManagInc, multifamily’s first-ever Corporate Social Responsibility (CSR) planning and consulting platform, was created by industry innovator Doug Miller. ManagInc’s Everyone Can Win® platform helps property management companies focus on their commitment to their three most important constituencies: their residents, their employees, and the communities they conduct business in. The Everyone Can Win® platform helps clients evaluate, measure, manage and enhance its three pillared CSR program. The focus on employee engagement and retention, resident satisfaction and retention, and giving back to society in a meaningful way creates a win-win for all involved – including a significant bottom line impact due to reduced employee and resident turnover. In addition, the ability to leverage a Socially Responsible Management Company Award positively impacts both employee and resident recruitment due to the importance of CSR to Millennials and others. http://www.ManagInc.com (business-to-business site), http://www.EveryoneCanWinAward.com (consumer-facing site). #csrmatters #csrtalk #everyonecanwin